Reported Saturday, Arrowhead Presents Plozasiran Data At AHA 2026 Showing 78% Lower Acute Pancreatitis Event Rate Versus Placebo And Sustained Triglyceride Reductions, Plus ARO-DIMER-PA Lowering LDL Cholesterol And Triglycerides
Benzinga Newsdesk 11 hours ago
News
Pooled SHASTA-3 and SHASTA-4 analysis showed plozasiran reduced acute pancreatitis event rates by 78% overall and 91% in sHTG patients with a recent history of acute pancreatitis versus placeboPALISADE open-label
- Pooled SHASTA-3 and SHASTA-4 analysis showed plozasiran reduced acute pancreatitis event rates by 78% overall and 91% in sHTG patients with a recent history of acute pancreatitis versus placebo
- PALISADE open-label extension showed sustained reductions in triglycerides and APOC3 with plozasiran through up to 36 months of treatment in patients with FCS
- Single doses of investigational dual-functional ARO-DIMER-PA produced mean LDL-C reductions of up to 65% and median triglyceride reductions of up to 78% from baseline